Yo @msbrinkman $DBVT trading like someone is accumulating .. or protecting an existing position at key technical level. ..

DAILY FETCH ALERT! $ELPW 113.7%, RNWWW 55.1%, CANC 73.5%, DBVT 55.6% High confidence signals from our AI models! 🚀 #StockMarket #Trading #Investing #HoundTrader houndtrader.com/daily-fetch?…

DBV Technologies Nasdaq: $DBVT DBV Technologies presented new positive data from the VITESSE study and previewed its recently initiated THRIVE study at EAACI 2026. The update adds clinical visibility to $DBVT’s allergy immunotherapy platform as food allergy treatment remains a major unmet medical need. @DBVTechnologies Link: stocktitan.net/news/DBVT/dbv… #Biotech #Allergy #ClinicalData #Stocks

$dbvt was waiting for 15.. but now i see is on MUTTONS 1st page.. so likely it gets to 12.

🚨 Biotech Stock News 6/9 @ Open $RNAC 18% Strategic Licensing Agreement for CAR-T $SPTX 8% Positive GlyphAgo™ Ph1 Data $ACTU 7% Elraglusib in BEACON2 Trial $TGTX 2% Positive Ph1 Data for BRIUMVI $ASND 2% Advances in Rare Endocrine Treatments $IRON 2% Update on Bitopertin for EPP $TNGX 1% Proposed $500M Public Offering $LLY 0% Foundayo delivers superior A1C control $ELOX 0% Pricing of $66M Offering $IPSC 0% CNTY-813 Preclinical Data $KYMR 0% First Participant Dosed in Ph1 $ZLAB 0% Approval of TIVDAK for cervical cancer $NBIX 0% INGREZZA for Tardive Dyskinesia Data $CPIX -1% Opaganib Receives FDA Designation $DBVT -1% New data from VITESSE Study $VTGN -1% ICH Safety Exposure for Fasedienol $ACOG -1% Positive results from BEACON study $CRVS -2% Soquelitinib Investment for Development $MRNA -3% Ph1/2 Study of mRNA Vaccine $GILD -3% ISL/LEN & KEYNOTE-D46 Update $SPRB -3% Tralesinidase Alfa data in MPS IIIB $IVVD -4% Ph3 Trial for VYD2311 $PALI -6% Potential of PALI-2108 for Crohn's $IDYA -7% Pricing of $300M Offering Shoutout to @Franca_ole for catching $RNAC early. WestGene adds another autoimmune CAR-T angle to watch. 🤔 More interest around in vivo mRNA CAR-T platforms beyond oncology See the image and comments for more details!

$DBVT DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 - DBV Technologies will present new data on its VIASKIN Peanut Patch at the EAACI Congress 2026. - Phase 3 VITESSE subgroup results in children aged 4–7 with asthma, other food allergies or atopic dermatitis showed statistically significant efficacy vs placebo, with responder rates broadly around 47% vs 15%. - DBV will also preview the Phase 2 THRIVEstudy design in approximately 250 infants aged 6–12 months, which will evaluate ad lib peanut consumption after three years of epicutaneous immunotherapy treatment. stocktitan.net/news/DBVT/dbv…

#DBV En moins d’une semaine : ✅ BLA confirmé au S1 2026 ✅ Priority Review visée ✅ THRIVE lancé ✅ Nouvelles données positives VITESSE à l’EAACI ✅ Goldman Sachs Healthcare Conference le 9 juin ✅ Préparation commerciale en cours Cours : proche des plus bas annuels. Le marché semble attendre une seule chose : 👉 “BLA Submitted” #DBVT #Biotech #FDA #PeanutAllergy #Healthcare #Investing $DBVT live.euronext.com/fr/product…

$DBVT I've located the person responsible for the VIASKIN Peanut Patch BLA submission.

📢 Biotech Stock News 6/3 @ Open $TGTX 10% BRIUMVI® Ph1 Trial Results $SYRE 7% SKYWAY Trial Enrollment Completion $NBIX 6% New CRENESSITY® data presentation $MAIA 6% FDA Clearance for THIO-101 Trial $PVLA 5% Completion of FDA Pre-NDA Meeting $CTMX 2% Expansion of Research Collaboration $ZBIO 2% Data from INDIGO Trial of Obexelimab $CATX 2% First Patient Dosed with [212Pb]VMT-α-NET $AMGN 2% New data across autoimmune diseases $DYN 2% Completion of Enrollment in ACHIEVE Trial $BIIB 2% Upcoming Kidney Presentations $NAMS 1% Upcoming Presentations at NLA Sessions $IDYA 1% Clinical Collaboration in Pancreatic Cancer $KYTX 1% Updated Miv-cel data shows efficacy $ARGX 1% New Efgartigimod Data in Myositis $JNJ 1% Nipocalimab reduces lupus disease activity $BMY 0% Evaluate Casdatifan for Kidney Cancer $SNDX 0% Revuforj® data presented at ASCO 2026 $CVKD 0% Showcase CAD-1005 and 12-LOX Platform $MNKD 0% Completion of Nintedanib Ph1b Study $PCVX 0% VAX-A1 Ph1 Study Participant Dosing $LXRX -1% Present Data at ADA 2026 $MDNAF -1% MDNA11 in Earlier Line Melanoma $TCRX -1% TSC-101 Manufacturing Agreement $TNYA -1% Interim data for TN-201 therapy $ATNM -2% New ATNM-400 Data in Lung Cancer $BMEA -2% Evaluate Icovamenib with Semaglutide $KURA -2% Darlifarnib for KRAS-Mutant Cancers $INAB -3% New Publication $LIXT -3% Registered Direct Offering $CABA -4% New Rese-cel data and updates $DBVT -4% First Participant Screened in THRIVE Study $CELC -4% Public Offering of Convertible Notes $NRXP -10% Pricing of Public Offering $MLYS -15% Pricing of $150M Offering $RNAZ -15% TTX-MC138 Ph1a Trial Completion See the image and comments for more details!

Toujours sur ma petite DBV technologies $DBVT 😤😤😤😤

Things are beginning to look pretty precarious. $DBVT

(1/3) Perceptive Advisors LLC Q126 13F Changes: NEW: $ADPT, $APLS, $CORT, $DBVT, $DAWN, $EDSA, $EOLS, $EVMN, $XGN, $DMRA, $IONS, $MRNA, $NMRA, $OCUL, $PHAT, $RVMD, $SRZN, $STRO, $TWST Increased: $AGLE, $ANRO, $AVR, $ASND, $AXSM, $BBNX, $BLLN, $BCRX, $CNTA, $CRVS, $CTMX, $DYN, $GH, $NRIX, $PRAX, $RLAY, $SABS, $SLDB, $TNGX, $TENX, $XFOR, $ZYME, $ROIV Decreased: $ADMA, $ABVX, $IVVD, $ADGM, $APGE, $AXGN, $BLTE, $DRUG

Vivo Capital LLC Q126 13F Changes: NEW: $ALXO, $ANTX, $AVBP, $CMPS, $OKUR, $SNSE Increased: $DRUG.CN, $CRVS, $DBVT, $ERAS, $PRAX Decreased: $ABVX, $ACRS, $COGT, $DYN, $GERN, $ORIC, $SLNO, $TERN, $VRDN CLOSED: $ABEO, $CDTX, $CTMX, $ENGNW, $PALI, $SLN, $VSTM, $ZBIO, $AVDL

(4/4) HighVista Strategies LLC Q126 13F Changes: CLOSED: $CNX, $CDTX, $MBU.F, $CMPX, $DBVT, $GTLB, $OFIX, $RBLX, $SNDK, $SCHW, $SEPN, $FOUR, $TMO, $UNF, $VST, $ALC.SW

MPM BIOIMPACT LLC Q126 13F Changes: NEW: $ACRS, $ALLO, $CORT, $CYTK, $DNTH, $FBRX, $MLTX, $TVTX, $VRDN, $ZYME Increased: $ABVX, $AGIO, $ARQT, $BLTE, $DBVT, $DYN, $EWTX, $ENGN, $EVMN, $LQDA, $GLUE, $ORIC, $PVLA, $RLAY, $RVMD, $SNDX, $TARS, $TRVI, $XENE, $URGN Decreased: $ALMS, $DRUG.CN, $CRVS, $ELYM, $NTRA, $STOK, $HOWL, $QURE CLOSED: $MDGL, $MAZE, $PTCT, $PTGX, $RAPT, $RCKT, $SRPT, $VTYX

Elmind Capital LP Q126 13F Changes: NEW: $ALMS, $DBVT Increased: $CGEM, $CTMX, $KALV, $TVTX, $UTHR, $PCVX, $URGN Decreased: $BCRX, $BMRN, $CGON, $EWTX, $VRDN, $WVE CLOSED: $DVAX, $LQDA

(2/3) Vestal Point Capital LP Q126 13F Changes: Increased: $MPLT, $GLUE, $MYGN, $NUVL, $NRIX, $OKUR, $RAPP, $RGNX, $RGEN, $RVMD, $SVRA, $SRRK, $TSHA, $VERA, $VYGR, $XENE, $ZBH, $IMTX Decreased: $ABVX, $ANRO, $IRON, $ELVN, $GERN, $GMED, $KALV, $OLMA, $SLDB, $TERN, $TYRA, $NYXH, $NVCR, $ALC.SW CLOSED: $ABT, $ALEC, $ACLX, $AXSM, $BDTX, $DBVT, $DAWN, $DXCM, $FATE, $GILD, $QQQ, $LNTH, $LENZ, $MRK, $MNMD, $MIRM, $PEN, $RZLT

(2/2) Logos Global Management LP Q126 13F Changes: Decreased: $GPCR, $TNGX, $PCVX, $VSTM, $CBIO, $PHVS CLOSED: $APLS, $ACLX, $RNA, $CDTX, $DBVT, $DAWN, $KYMR, $MREO, $NGNE, $NRIX, $NUVB/WS, $JAZZ, $KNSA, $IMTX, $QURE